Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.
Journal: Clinical and translational allergy
Published: July 31, 2025
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Journal: The journal of allergy and clinical immunology. In practice
Published: May 16, 2025
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Journal: The journal of allergy and clinical immunology. In practice
Published: May 16, 2025
Safety and Efficacy of Intravenous Immune Globulin 10% (BIVIGAM®) in Children with Primary Immune Deficiency.
Journal: Journal of clinical immunology
Published: December 17, 2024
Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study.
Journal: Frontiers in neurology
Published: November 06, 2024
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
Journal: The New England journal of medicine
Published: May 31, 2024
IVIG response in pediatric acute-onset neuropsychiatric syndrome correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures.
Journal: Frontiers in immunology
Published: February 08, 2024
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
Journal: Journal of clinical immunology
Published: March 16, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Journal: Frontiers in immunology
Published: November 28, 2022
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Journal: Clinical and experimental immunology
Published: June 22, 2022
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
Journal: Journal of clinical immunology
Published: May 31, 2022
Last Updated: 01/07/2026